-
Mashup Score: 73
There have been major advances in cardiovascular pharmacotherapy in recent decades, but many evidence gaps remain. Our patients have high expectations of cardio
Source: OUP AcademicCategories: Healthcare Professionals, Latest HeadlinesTweet
-
Mashup Score: 27
There have been major advances in cardiovascular pharmacotherapy in recent decades, but many evidence gaps remain. Our patients have high expectations of cardio
Source: OUP AcademicCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 6
There have been major advances in cardiovascular pharmacotherapy in recent decades, but many evidence gaps remain. Our patients have high expectations of cardio
Source: OUP AcademicCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 3
There have been major advances in cardiovascular pharmacotherapy in recent decades, but many evidence gaps remain. Our patients have high expectations of cardio
Source: OUP AcademicCategories: Cardiology News and Journals, Latest HeadlinesTweet
-
Mashup Score: 6New pharmacological agents and novel cardiovascular pharmacotherapy strategies in 2022 - 11 month(s) ago
Abstract. Cardiovascular diseases (CVD) remain the leading cause of death worldwide and pharmacotherapy of most of them is suboptimal. Thus, there is a clear un
Source: OUP AcademicCategories: Cardiology News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Obesity Management Learning Hub | ACP Online - 1 year(s) ago
This comprehensive, up-to-date learning series provides practical guidance to support physicians and their teams in treating patients with obesity. Learn more.
Source: www.acponline.orgCategories: General Medicine Journals and Societies, Latest HeadlinesTweet-
During @ObesityCareWeek (Feb. 27-March 3, 2023), explore ACP's Obesity Management Hub resources to improve the counseling and treatment of #obesity: https://t.co/CFXlxINiqU #OCW2023 Free #CME/#MOC for ACP members. 🔸 Lifestyle modification 🔸 #Pharmacotherapy 🔸 #BariatricSurgery https://t.co/7kuoyBa8V0
-
-
Mashup Score: 1Reducing the Risk of Mortality in Chronic Obstructive Pulmonary Disease With Pharmacotherapy: A Narrative Review - 1 year(s) ago
In 2020, chronic obstructive pulmonary disease (COPD) was the fifth leading cause of death in the United States excluding COVID-19, and its mortality burden has been rising since the 1980s. Smoking cessation, long-term oxygen therapy, noninvasive ventilation, and lung volume reduction surgery have had a beneficial effect on mortality; however, until recently, the effects of pharmacologic…
Source: Mayo Clinic ProceedingsCategories: Latest Headlines, PulmonologyTweet
-
Mashup Score: 1Wolters Kluwer Health - 1 year(s) ago
JavaScript Error JavaScript has been disabled on your browser. You must enable it to continue. Here’s how to enable JavaScript in the following browsers: Internet Explorer From the Tools menu, select Options Click the Content tab Select Enable JavaScript Firefox From the Tools…
Source: lww.comCategories: Healthcare Professionals, Latest HeadlinesTweet
-
Mashup Score: 0Challenges in the Pharmacotherapy of COPD Subtypes - 1 year(s) ago
Editorial DOI: 10.1016/j.arbres.2022.11.005 Available online 2 December 2022 Challenges in the Pharmacotherapy of COPD Subtypes Visits … Download…
Source: www.archbronconeumol.orgCategories: Latest Headlines, PulmonologyTweet
-
Mashup Score: 2Seminar All About Clinical Trials (AACT) - 1 year(s) ago
Check out the cardiology knowledge from European Society of Cardiology
Source: esc365.escardio.orgCategories: Cardiology News and Journals, Latest HeadlinesTweet
RT @ESC_Journals: The year in cardiovascular #pharmacotherapy 2022: Landmark evidence at a glance 💊 https://t.co/NucEKB587g @AgewallStefa…